IRCT20171007036623N1 IRCT 2017-11-29 Shahid Beheshti University of Medical Sciences The Effect of Tacrolimus in patients with recurrent implantation failure Investigation of gene expression and secretion of P53, LIF, IL_10, IL-17 after administration of tacrolimus in endometrial and uterine fluid in patients with repeated implantation failure: Clinical trial 2017-12-11 anticipated 10 Complete https://irct.ir/trial/27322 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Recurrent Implantation Failure. Intervention 1: Prescription of Tacrolimus in the second menstrual cycle for up to 16 days (until 2 days before second biopsy) with 1-3 mg per day upon on IFN-g/IL-4 ratio: Prescription of 1 mg per day if this ratio is equal or more than10.3 and less than 13 Prescript. Intervention 2: Prescription of Tacrolimus in third cycle of menstruation from 2 days before embryo transfer until 14 days after embryo transfer for overall 16 days with 1-3 mg per day upon on IFN-g/IL-4 ratio. Prescription of 1 mg per day if this ratio is equal or mo. Yes - There is a plan to make this available What will be shared: Share with other studies and collaborate with other research and clinical centers to increase the effectiveness of the study When: After the study is completed and 6 months after the results are printed To whom: Research Centers and Study Groups of Basic Sciences and Clinical Sciences Conditions: It is possible to use the analyzed results after receiving written permission from the executor Where to obtain: Principal Investigator or corresponding author of study How to obtain: After a written request for the use of results in clinical studies Comments: